Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.

Journal Article (Journal Article;Review)

Glioblastoma (GBM) is a devastating disease with an extremely poor prognosis. Immunotherapy via adoptive cell transfer (ACT), especially with T cells engineered to express chimeric antigen receptors (CAR), represents a particularly promising approach. Despite the recent success of CAR T cells for blood cancers, the question remains whether this powerful anticancer therapy will ultimately work for brain tumors, and whether the primary immunologic challenges in this disease, which include antigenic heterogeneity, immune suppression, and T-cell exhaustion, can be adequately addressed. Here, we contextualize these concepts by reviewing recent developments in ACT for GBM, with a special focus on pioneering clinical trials of CAR T-cell therapy.

Full Text

Duke Authors

Cited Authors

  • Choi, BD; Maus, MV; June, CH; Sampson, JH

Published Date

  • April 1, 2019

Published In

Volume / Issue

  • 25 / 7

Start / End Page

  • 2042 - 2048

PubMed ID

  • 30446589

Pubmed Central ID

  • PMC6445734

Electronic International Standard Serial Number (EISSN)

  • 1557-3265

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-18-1625


  • eng

Conference Location

  • United States